Potential of Mesenchymal Stem Cell based application in Cancer.

  • Sushilkumar Ramdasi Mail Regenerative Medicine Group, Reliance Life Sciences Pvt. Ltd. Dhirubhai Ambani Life Sciences Centre, R-282, TTC Area of MIDC, Thane-Belapur Road, Rabale, Navi Mumbai - 400701. India.
  • Shabari Sarang Regenerative Medicine Group, Reliance Life Sciences Pvt. Ltd. Dhirubhai Ambani Life Sciences Centre, R-282, TTC Area of MIDC, Thane-Belapur Road, Rabale, Navi Mumbai - 400701. India.
  • Chandra Viswanathan Regenerative Medicine Group, Reliance Life Sciences Pvt. Ltd. Dhirubhai Ambani Life Sciences Centre, R-282, TTC Area of MIDC, Thane-Belapur Road, Rabale, Navi Mumbai - 400701. India.
Keywords:
Anti-cancer, Cancer, Mesenchymal Stem Cells, Tropism, Tumor

Abstract

Stem cell based treatments are being increasingly explored for their possible potential to treat various cancers. Mesenchymal stem cells believed to possess anti-tumor potential and are preferred for their properties like immune privileged nature, ability to migrate to the site of tumor and capability for multilineage differentiation. This tumor tropism property of MSCs could be utilized to deliver anti-tumor biological agents to the site of tumor. In a tumor micro-environment, MSCs are believed to play both, a pro-tumorigenic and an anti-tumorigenic role. However, this is dependent on a host of factors like, types of MSCs, its source, type of cancer cell line under investigation, in vivo or in vitro conditions, factors secreted by MSCs and interactions between MSCs, host’s immune cells and cancer cells. Among several cytokines secreted by MSCs, TRAIL (Tumor necrosis factor related apoptosis inducing ligand) is reported to be pro-apoptotic for tumor cells. The MSCs from bone marrow and adipose tissue have been studied quite extensively. Deriving MSCs from sources such as umbilical cord blood and umbilical cord tissue is relatively easier. Umbilical cord tissue preferred for MSC derivation due to their abundant availability. These MSCs believed to up regulate TRAIL expression in MSC-cancer cell co-culture system resulting in induction of apoptosis in cancer cells. However, umbilical cord tissue derived MSCs needs to be studied for expression pattern of TRAIL in a co-culture system. We present a review article on different studies reporting both, pro-tumorigenic and anti-tumorigenic properties of MSCs.

References

Gilman A. The initial clinical trial of nitrogen mustard. Am J Surg. 1963; 105: 574–578.

Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour-initiating cells. Nature.2004; 432: 396–401.

O’Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007; 445: 106–110.

Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res.2007; 67: 1030– 1037.

Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells — perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006b; 66: 9339–9344.

Becker AJ, McCulloch EA, Till JE. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature.1963; 197: 452-4.

Siminovitch L, McCulloch EA, Till JE. The distribution of colony-forming cells among spleen colonies. Journal of Cellular and Comparative Physiology. 1963; 62: 327-36.

Pessina A, Gribaldo L.The key role of adult stems cells: therapeutic perspectives. Curr Med Res Opin. 2006; 22(11): 2287-2300.

Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science.1999; 284(5411): 143-147.

Deasy BM, Li Y, Huard J. Tissue engineering with muscle-derived stem cells. Curr Opin Biotechnol. 2004; 15(5): 419-423.

Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001; 7(2): 211-228.

De Bari C, Dell'Accio F, Tylzanowski P. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum. 2001; 44(8): 1928-1942.

Zarnett R, Salter RB. Periosteal neochondrogenesis for biologically resurfacing joints: its cellular origin. Can J Surg. 1989; 32(3): 171-174.

Tian LL, Yue W, Zhu F, et al. Human Mesenchymal Stem Cells Play a Dual Role on Tumor Cell Growth In Vitro and In Vivo. J of Cell Physio. Published online in Wiley Online Library (wiley online library.com), 10 November 2010.

Friedenstein AJ, Piatetzky-Shapiro II, Petrakova KV .Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol.1966; 16: 381-390.

Friedenstein AJ, Petrakova KV, Kurolesova AI, et al. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation.1968; 6: 230-247.

Cooper K, Sen Majumdar A, Viswanathan C. Derivation, expansion and characterisation of clinical grade Mesenchymal stem cells from umbilical cord matrix using cord blood serum. International journal of stem cells. 2010; 3(2): 119-128.

Tipnis S, Viswanathan C, SenMajumdar A. Immunosuppressive Properties of Human Umbilical Cord Derived Mesenchymal Stem Cells: Role of B7-H1 and IDO. Immunology and Cell Biology Journal. 2010; 88: 795-806.

Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8: 315–317.

Prockop DJ. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther. 2009; 17: 939–946.

Lazarus HM, Haynesworth SE, Gerson SL, et al. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplantation. 1995; 16(4): 557–564.

Horwitz EM, Prockop DJ, Lorraine A, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta, Nature Medicine. 1999; 5(3): 309–313.

Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004; 363(9419): 1439–1441.

Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus host disease: a phase II study. Lancet. 2008; 371(9624): 1579–1586.

Chen S, Liu Z, Tian N, et al. Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. Journal of Invasive Cardiology. 2006; 18(11): 552– 556.

Dai LJ, Li HY, Guan LX, et al. The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cirrhosis. Stem Cell Res.2009; 2: 16-25.

Zhang ZX, Guan LX, Zhang K, et al. combined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injury. Cytotherapy.2008; 10: 134-139.

Strauer BE, Brehm M, Zeus T, et al. Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT Study. J Am CollCardiol.2005; 46: 1651-1658.

Javazon EH, Beggs KJ, Flake AW. Mesenchymal stem cells: paradoxes of passaging. Experimental Hematology. 2004; 32(5): 414–425.

Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell mediated cytolysis. Annual Review of Immunology. 2001; 19: 197–223.

Maestroni GJ, Hertens E, Galli P. Factors from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice. Cell Mol Life Sci, 1999; 55: 663-667.

Sun XY, Nong J, Qin K, et al. Mesenchymal stem cell- mediated cancer therapy: A dual-targeted strategy of personalized medicine. World J Stem Cells. 2011; 3(11): 96-103.

Pendleton C, Li Q, Chesler DA, et al. Mesenchymal Stem Cells Derived from Adipose Tissue vs Bone Marrow: In Vitro Comparison of Their Tropism towards Gliomas. PLoS ONE. 2013; 8(3): e58198.

Nakamura K, Ito Y, Kawano Y, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 2004; 11: 1155–1164.

Kosztowski T, Zaidi HA, Quinones-Hinojosa A. Applications of neural and mesenchymal stem cells in the treatment of gliomas. Expert Rev Anticancer Ther. 2009; 9: 597–612.

Lamfers M, Idema S, van Milligen F, et al. Homing properties of adipose-derived stem cells to intracerebral glioma and the effects of adenovirus infection. Cancer Lett. 2009; 274: 78–87.

Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med.1986; 315: 1650-1659.

Studeny M, Marini FC, Champlin RE, et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res.2002; 62: 3603-3608.

Kidd S, Caldwell L, Dietrich M, et al. Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy.2010; 12: 615-625.

Kidd S, Spaeth E, Dembinski JL, et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding micro-environments using in vivo bioluminescent imaging. Stem Cells.2009; 27: 2614-2623.

Menon LG, Picinich S, Koneru R M, et al. Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells.2007; 25: 520-528.

Loebinger MR, Kyrtatos PG, Turmaine M, et al. Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles. Cancer Res.2009; 69: 8862-8867.

Khakoo AY, Pati S, Anderson SA, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J Exp Med.2006; 203: 1235-1247.

Sasportas LS, Kasmieh R, Wakimoto H, et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA.2009; 106: 4822-4827.

Roisin M D, Sonja K, Frank P B, et al. Advances in mesenchymal stem cell-mediated gene therapy for cancer. Stem Cell Research & Therapy. 2010; 1:25.

Nakamizo A, Marini F, Amano T, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res2005; 65: 3307-3318.

Studeny M, Marini FC, Dembinski JL, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst.2004; 96:1593-1603.

Wels J, Kaplan RN, Rafi i S, et al. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev.2008; 22:559-574.

Dwyer RM, Potter-Beirne SM, Harrington KA, et al. Monocyte chemotactic protein-1 (MCP-1) secreted by primary breast tumors stimulates migration of mesenchymal stem cells (MSCs). Clin Cancer Res.2007; 13: 5020-5027.

O’Donoghue K, Chan J, Fuente J, et al. Microchimerism in female bone marrow and bone decades after fetal mesenchymal stem-cell trafficking in pregnancy. Lancet.2004; 364(9429): 179–182.

Chen X, Lin X, Zhao J, et al. A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol. Ther. 2008; 16: 749–756.

Ren C, Kumar S, Chanda D, et al. Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells. 2008; 26: 2332–2338.

Li X, Lu Y, Huang W, et al. In vitro effect of adenovirus-mediated human Gamma Interferon gene transfer into human mesenchymal stem cells for chronic myelogenous leukemia, Hematol. Oncol. 2006; 24: 151– 158.

Kanehira M, Xin H, Hoshino KT, et al. Targeted delivery of NK4 to multiple lung tumors by bone marrow- derived mesenchymal stem cells. Cancer Gene Ther. 2007; 14: 894–903.

Grisendi G, Bussolari R, Cafarelli L, et al. Adipose- derived mesenchymal stem cells as stable source of tumor necrosis factor related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res. 2010; 70: 3718– 3729.

Komarova S, Kawakami Y, Stoff-Khalili MA, et al. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther. 2006; 5: 755 -766.

Zhu W, W Xu, R Jiang, et al. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol. 2006; 80: 267–274.

Yu JM, ES Jun, YC Bae, et al. Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells Dev. 2008; 17: 463–473.

Galderisi U, Giordano A, Paggi Marco G. The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents. World J Stem Cells.2010 February 26; 2(1): -12.

Keiko A, Kenichi K, Masumi N, et al. Umbilical Cord Blood-Derived Mesenchymal Stem Cells Inhibit, But Adipose Tissue-Derived Mesenchymal Stem Cells Promote, Glioblastoma Multiforme Proliferation. STEM CELLS AND DEVELOPMENT. 2013; 22(9).

Okumura T, Wang SS, Takaishi S, et al. Identification of a bone marrow-derived mesenchymal progenitor cell subset that can contribute to the gastric epithelium. Lab. Invest. 2009; 89: 1410–1422.

Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007; 449: 557–563.

R Lis, C Touboul, P Mirshahi, et al. Tumor associated mesenchymal stem cells protects ovarian cancer cells from hyperthermia through CXCL12. Int. J. Cancer. 2010.

Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 2003; 102: 3837–3844.

Kucerova L, Matuskova M, Hlubinova K, et al. Tumor cell behaviour modulation by mesenchymal stromal cells. Molecular Cancer. 2010; 9: article 129.

Roorda BD, Elst A, Kamps WA, et al. Bone marrow- derived cells and tumor growth: Contribution of bone marrow-derived cells to tumor micro-environments with special focus on mesenchymal stem cells. Crit Rev Oncol Hematol. 2009; 69: 187–198.

Kang SG, Jeun SS, Lim JY, et al. Cytotoxicity of human umbilical cord blood-derived mesenchymal stem cells against human malignant glioma cells. Childs Nerv Syst. 2008 Mar; 24(3): 293-302.

Qiao L, Zhao TJ, Wang FZ, et al. NFkappa B downregulation may be involved the depression of tumor cell proliferation mediated by human mesenchymal stem cells. Acta Pharmacol Sin.2008; 29: 333-340.

Ohlsson LB, Varas L, Kjellman C, et al. Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix. Exp Mol Pathol. 2003; 75: 248-255.

Otsu K, Das S, Houser SD, et al. Concentration- dependent inhibition of angiogenesis by mesenchymal stem cells. Blood. 2009; 113: 4197-205.

Ayuzawa R, Doi C, Rachakatla RS, et al. Naive human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo. Cancer Lett. 2009; 280: 31-7.

Doi C, Maurya DK, Pyle MM, et al, Tamura M. Cytotherapy with naive rat umbilical cord matrix stem cells significantly attenuates growth of murine pancreatic cancer cells and increases survival in syngeneic mice. Cytotherapy. 2010; 12: 408-17.

Chanda D, Isayeva T, Kumar S, et al. Therapeutic Potential of Adult Bone Marrow–Derived Mesenchymal Stem Cells in Prostate Cancer Bone Metastasis. Clin Cancer Res. December 1, 2009; 15: 7175.

Chen G, Shukeir N, Potti A, et al. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer. 2004; 101: 1345–1356.

Loebinger MR, Janes SM. Stem cells as vectors for antitumour therapy. Thorax.2010; 65: 362-369.

Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005; 434: 843–850.

Duncan AW, Rattis FM, DiMascio LN, et al. Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance, Nat. Immunol. 2005; 6: 314–322.

Androutsellis-Theotokis A, Leker RR, Soldner F, et al. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature. 2006; 442: 823–826.

Cousin B, Ravet E, Poglio S, et al. Adult stromal cells derived from human adipose tissue provoke pancreatic cancer cell death both in vitro and in vivo. PLoS One. 2009; 4: e6278.

Waterman RS, Tomchuck SL, Henkle SL, et al. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One. 2010; 5: e10088.

Waterman RS, Henkle SL, Betancourt AM. Mesenchymal Stem Cell 1 (MSC1)-Based Therapy Attenuates Tumor Growth Whereas MSC2-Treatment Promotes Tumor Growth and Metastasis. PLoS One. 2012; 7(9): e45590.

Shuichi M, Ting Y, Akifumi M, et al. Cancer stem cells maintain a hierarchy of differentiation bycreating their niche. Int. J. Cancer. 2014; 135: 27–36.

How to Cite
1.
Ramdasi S, Sarang S, Viswanathan C. Potential of Mesenchymal Stem Cell based application in Cancer. Int J Hematol Oncol Stem Cell Res. 9(2):95-103.
Section
Articles